法布瑞氏症治療市場:現況分析與預測（2023-2030）

Fabry Disease Treatment Market: Current Analysis and Forecast (2023-2030)

出版日期: 2024年01月30日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 149 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

由於肥胖盛行率不斷增加，法布瑞氏症治療市場預計將穩定成長約 7.1%，而肥胖在法布瑞氏症的進展中扮演重要角色。例如，根據《2022 年世界肥胖地圖集》，預計到 2030 年，全球將有 10 億人（五分之一的女性和七分之一的男性）患有肥胖症。已經引入了許多新療法來治療這些遺傳性疾病。其他幾個因素，例如人口中遺傳性疾病數量的增加，正在以穩定的速度推動法布瑞氏症治療市場。例如，根據世界衛生組織 (WHO) 的數據，所有活產嬰兒中約有 2-5% 患有遺傳性疾病和先天性畸形。

依給藥方式，市場分為口服給藥部分及靜脈給藥部分。 2022年全球法布瑞氏症治療市場中，口服用藥將佔最大份額。由於患者對口服藥物的需求不斷增加，該細分市場佔據了市場主導地位。據報道，片劑因其高效的成分和易於食用而成為所有劑型中消耗最多的固體形式。口服給藥正在推動這一領域的成長，因為它對消費者來說更方便且更便宜。因此，由於上述原因，口服製劑將在2022年佔據較大的市場份額。

根據治療，市場分為底物減少療法、酵素替代療法、伴侶療法等。由於其有效的治療效果，酵素替代療法預計將在預測期內佔據主要份額。 Fabrazyme 可恢復 ALPHA-半乳糖甘□ A 的水平，從而分解體內的脂質並減輕法布瑞氏症的症狀。例如，根據2023年8月法布瑞氏症新聞報道，酵素替代療法已被證明對法布瑞氏症患者非常有幫助。除此之外，快速診斷測試的使用激增也推動了該領域的成長。因此，預計酵素替代療法類別在預測期內的應用中將表現出較高的複合年增長率。

為了更了解法布瑞氏症治療的市場介紹，市場為北美（美國、加拿大等北美地區）、歐洲（德國、英國、法國、西班牙、義大利等歐洲地區）、亞太地區（中國、中國和其他地區）。、日本、印度、亞太地區其他地區）和世界其他地區。由於遺傳性疾病的增加、法布瑞氏症患者數量的增加以及開發有效治療方法的投資增加，北美在 2022 年將主導全球法布瑞氏症治療市場。例如，根據美國國家法布瑞氏症基金會的數據，目前美國法布瑞氏症基因帶因者人數到2023年將超過11,000人。政府機構已啟動提高認識計劃，以預防這些遺傳性神經系統疾病，並為患者提供有效的護理。因此，2022年北美將佔據很大的市場份額。

Fabry disease is a rare genetic disorder caused by the deficiency of an enzyme called alpha-galactosidase A. This deficiency leads to the accumulation of certain fatty substances in the body, affecting various organs and systems. Symptoms often start in childhood or adolescence and can include pain, skin lesions, gastrointestinal issues, and problems with the heart, kidneys, and nervous system. Early diagnosis and management are crucial to help alleviate symptoms and prevent complications. Fabry disease treatment is gaining prominence in the market owing to the increasing prevalence of fabry disease, rising cases of obesity, and rising demand for oral drugs. For instance, according to the National Institute of Health, classic fabry disease mutations are seen in approximately 1 in 30,000 males, and atypical presentations are associated with about 1 in 15,000 males and 1 in 23,000 females. Several factors, including a surge in the increasing awareness regarding inherited disorders, an increasing geriatric population, and increased investments from the government, public, and private sectors in healthcare departments are driving the growth of the market during the forecast period. According to the World Health Organization (WHO), the share of people aged above 60 will rise to 1.4 billion by 2030 while this share will increase to 2.1 billion by 2050 which would be more than double the share of the geriatric population in the year 2020 i.e., 1 billion.

The Fabry Disease Treatment Market is expected to grow at a steady rate of around 7.1% owing to the increased prevalence of obesity which plays an important role in the progression of fabry disease. For instance, as per the World Obesity Atlas 2022, estimations are such that 1 billion people worldwide, comprising one in five women and one in seven men will be suffering from obesity by the year 2030. Many new therapies are being introduced for treating these inherited disorders. Several other factors, such as rising genetic disorders among people are also driving this market of fabry disease treatment at a steady rate. For instance, according to the World Health Organization, genetic disorders and congenital abnormalities occur in about 2-5% of all live births.

Based on the mode of administration, the market is bifurcated into oral and intravenous segments. The oral segment held the maximum share in the global market of fabry disease treatment in 2022. This segment dominated the market because of the rising demand for oral drugs among patients. Tablets are reported to be the most consumed solid dosage forms among all medication forms, because of their highly effective composition, and ease of consumption. The oral mode of drug administration is much more convenient and easy on pockets for consumers, boosting this segment's growth. Hence, the oral segment held a significant share of the market in 2022 due to the above reasons.

Based on treatment, the market is categorized into substrate reduction therapy, enzyme replacement therapy, chaperone treatment, and others. The enzyme replacement therapy segment is expected to hold a significant share of the market in the forecast period owing to the efficient results of the therapy. Fabrazyme restores levels of alpha-galactosidase A. This allows the body to break down lipids and relieve the symptoms of fabry disease. For instance, according to Fabry Disease News in August 2023, enzyme replacement therapy has proved to be extremely helpful to fabry patients. Apart from this, the surge in the usage of rapid diagnostic tests is also impelling the growth of this segment. Hence, the enzyme replacement therapy category is expected to witness a higher CAGR during the forecast period amongst applications.

For a better understanding of the market adoption of fabry disease treatment, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America dominated the global fabry disease treatment market in 2022 due to the increasing genetic disorders, increased fabry disease cases, and rising investments in developing effective therapeutics. For instance, according to the National Fabry Disease Foundation, the number of individuals carrying the Fabry disease gene in the U.S. at over 11,000 according to currently published statistics of 2023. Government organizations are initiating awareness programs to prevent these inherited neurological disorders and provide efficient care to patients. Thus, North America held a significant share of the market in the year 2022.

Some of the major players operating in the market include Pfizer Inc.; Merck KGaA; Sanofi; Biocare Medical, LLC; Lilly; Teva Pharmaceutical Industries Ltd.; MITSUBISHI CHEMICAL GROUP CORPORATION; Bristol-Myers Squibb Company; GSK plc.; Bayer AG.

1 MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Fabry Disease Treatment Market
2.2. Research Methodology of the Fabry Disease Treatment Market
2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE FABRY DISEASE TREATMENT MARKET

6 FABRY DISEASE TREATMENT MARKET REVENUE (USD BN), 2020-2030F

7 MARKET INSIGHTS BY MODE OF ADMINISTRATION

7.1. Oral
7.2. Intravenous

8 MARKET INSIGHTS BY TREATMENT

8.1. Substrate Reduction Therapy
8.2. Enzyme Replacement Therapy
8.3. Chaperone Treatment
8.4. Others

9 MARKET INSIGHTS BY REGION

9.1. North America
- 9.1.1. U.S.
- 9.1.2. Canada
- 9.1.3. Rest of North America
9.2. Europe
- 9.2.1. Germany
- 9.2.2. U.K.
- 9.2.3. France
- 9.2.4. Italy
- 9.2.5. Spain
- 9.2.6. Rest of Europe
9.3. Asia-Pacific
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. India
- 9.3.4. Rest of Asia-Pacific
9.4. Rest of World